Article

Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats.

Institute of Pharmacology, Polish Academy of Sciences, PL 31-343 Kraków, Poland.
Neuropharmacology (Impact Factor: 4.82). 07/2002; 42(8):1024-30. DOI: 10.1016/S0028-3908(02)00055-2
Source: PubMed

ABSTRACT In spite of intensive research, the problem of treating antidepressant-resistant depressive patients has not yet been solved. The authors previously reported that combined administration of imipramine and the uncompetitive NMDA receptor antagonist amantadine reduced immobility time in the forced swimming test in rats to a much greater extent than either treatment alone. The present paper investigates the possibility of synergistic interactions between three antidepressants (imipramine, venlafaxine, fluoxetine) with three uncompetitive NMDA receptor antagonists (amantadine, memantine and neramexane). Most combinations resulted in synergistic (hyperadditive) antidepressive-like effects in the forced swim test. Most interesting was the observation that fluoxetine, which was inactive when given alone, showed a positive effect when combined with amantadine (10 and 20 mg/kg), memantine (2.5 and 5 mg/kg) or neramexane (2.5 and 5 mg/kg). The specificity of these observations is supported by control open field studies, which demonstrated no significant increase, or even a decrease in general locomotion after coadministration of the compounds. The present results suggest that the combination of traditional antidepressant drugs and NMDA receptor antagonists may produce enhanced antidepressive effects, and this is of particular relevance for antidepressant-resistant patients.

0 Followers
 · 
57 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease is a neurogenerative disease characterized by significant worsening of memory, disorders in the emotional sphere, and impairment of cognitive and motor functions. Agonists of NMDA receptors are used as potential therapeutic agents for correction of the above disorders, and memantine is one of such drugs. This agent decelerates the progressive development of neurodegenerative processes. It demonstrated a neuromodulatory action on motor behavioral phenomena in 2- and 13-month-old rats placed in nowel conditions of free behavior; estimation was performed before and after peroral introduction of 10 mg/kg memantine. Videorecording of the animals' behavior with subsequent analysis of the records was used in the experiments. According to the obtained data, memantine decreased, in general, motor activity of the rats, increased the duration of episodes of their quiet standstill state, and, simultaneously, somewhat increased the intensity of research phenomena. These results show that memantine weakens the state of fear and anxiety related to potential dangers in an unknown surrounding, promotes manifestations of the research reflex, and makes adaptation of the rats to novel conditions more rapid.
    Neurophysiology 01/2015; 46(5). DOI:10.1007/s11062-015-9472-7 · 0.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A great deal of evidence suggests that virtually all antidepressant treatments induce a dopaminergic behavioral supersensitivity. We have suggested that this effect may play a key role not only in the antidepressant effect of these treatments, but also in their ability to induce a switch from depression to mania. In 2003-4 we found that the sensitization of dopamine receptors induced by imipramine is followed, after imipramine withdrawal, by a desensitization of these receptors associated with a depressive-like behavior assessed in the forced swimming test. The dopamine receptor sensitization can be prevented by MK-801, an NMDA receptor antagonist, but not by currently used mood stabilizers (lithium, carbamazepine, valproate). These observations led us to suggest - and later confirm - with preliminary clinical observations that memantine may have an acute antimanic and a long-lasting mood-stabilizing effect in treatment-resistant bipolar disorder patients. Here we present data showing that memantine prevents not only the dopamine receptor sensitization induced by imipramine, as observed with MK-801, but also the ensuing desensitization and the associated depressive-like behaviorq observed after antidepressant withdrawal.
    European Journal of Pharmacology 02/2015; 752. DOI:10.1016/j.ejphar.2015.01.041 · 2.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The problem of antidepressant-resistant depression has necessitated finding ways of augmenting the actions of currently existing antidepressants. The present studies investigate the possibility of synergistic interactions between nitric oxide (NO) synthase inhibitors and antidepressants in the mouse forced swim test (FST), a pre-clinical test of antidepressant activity. Treatment with a behaviourally subactive dose of the NO synthase inhibitor NG-nitro-l-arginine (l-NA) (3 mg/kg) augmented the behavioural effect of the tricyclic antidepressant imipramine. In a similar fashion l-NA (3 mg/kg) augmented the effect of the selective serotonin re-uptake inhibitor (SSRI) fluoxetine but not the noradrenaline re-uptake inhibitor, reboxetine in the FST. The interaction observed between l-NA and fluoxetine generalised to other selective serotonin re-uptake inhibitors, namely, sertraline and citalopram in the FST. Treatment with a subactive dose of the neuronally selective NO synthase inhibitor, 7-nitroindazole (30 and 50 mg/kg), augmented the behavioural effects of imipramine and fluoxetine, respectively. Thus inhibition of NO synthase enhances the activity of antidepressants that work via a serotonergic mechanism in the FST. The results of the present investigation support a view that antidepressant effects, or enhancement of such effects in the FST, may be elicited via NO synthase inhibition. Furthermore, these data raise the possibility that inhibition of NO synthase could be used as a strategy to enhance the clinical efficacy of serotonergic antidepressants.
    European Neuropsychopharmacology 08/2004; 14(4):274-281. DOI:10.1016/S0924-977X(03)00183-4 · 5.40 Impact Factor